Twelve universities and 3 education groups filed a lawsuit against the NIH and HHS, challenging a 15% cap on research grant funding. A federal judge issued a temporary restraining order, halting the cuts while litigation proceeds. A hearing is set for February 21, 2025, and states and institutions are pushing for permanent relief.
Laptop displaying logo of The National Institutes of Health
Adobe Stock 406657254 by monticellllo)
In a separate case against the National Institutes of Health (NIH) and The US Department of Health and Human Services (HHS), also filed Monday February 10, 2025, 12 universities and 3 higher education groups (Plaintiffs) submitted a claim against the NIH and HSS (Defendants) to the United States District Court for the District of Massachusetts, requesting injunctive relief from the new NIH policy that placed a 15% cap on facilities and administration (F & A) costs for NIH research grants. These entities include,
The Association of American Universities, American Council on Education Association of Public and Land-Grant Universities, Brandeis University, Brown University, The Regents of the University of California, The California Institute of Technology, Carnegie Mellon University, The University of Chicago, Cornell University, The George Washington University, Johns Hopkins University, Massachusetts Institute of Technology, Trustees of the University of Pennsylvania, University of Rochester, and Trustees of Tufts College.
In their claim, the plaintiffs argue that the NIH has completely ignored existing statutes (laws made by legislative bodies) that “prohibit[s] HHS or NIH from spending appropriated funds “to develop or implement a modified approach to” the reimbursement of “indirect costs” and “deviations from negotiated rates (page 4).” The plaintiffs state that the administration had previously attempted to reduce indirect cost rates in 2017, which Congress blocked with provisions made to maintain the existing regulatory framework for indirect costs.
The recent policy change would directly violate those provisions made by Congress in 2017. The claim further explains that a continuance of this policy change from NIH would lead to devastating effects, crippling institutions across the nation from being able to continue essential medical and scientific research, potentially leading smaller institutions to close entirely.
In a Tuesday, February 11, 2025, morning email to the Johns Hopkins community, President Ronald J. Daniels, CM; and the dean of the medical faculty and Johns Hopkins University University School of Medicine and CEO of Johns Hopkins Medicine, Theodore L. DeWeese, broke the news of the lawsuit, and the importance of fighting a policy change that would be detrimental to the life-saving research conducted by the institution. It was discussed how imposing this funding cap on indirect research costs would decimate research at universities across the nation.
“We could point to any number of examples of how these dramatic cuts will impact our research and patient care mission, but let us offer just one: NIH funding supports approximately 600 current and ongoing clinical trials at Johns Hopkins,” the email said. “This includes open clinical trials in cancer, pediatrics and children’s health, heart and vascular studies, and the aging brain, among many others. The NIH funding cut endangers these trials and many more like them into the future. And these trial participants are our patients. The care, treatments, and medical breakthroughs provided to them and their families are not ‘overhead’ – they offer meaningful hope and scientific expertise, often when it’s needed most.”
US District Judge Angel Kelley temporarily restrained the NIH 15% funding cap on Monday, February 10, 2025, in her response to the claim filed by 22 states against the NIH, with a hearing set for February 21, 2025. A third lawsuit, also filed on Monday, February 10, 2025, requested that the injunction be applied to the 22 states suing and to all states across the nation. The pause was extended by Kelley late Monday, February 10, 2025. night to be applied as nationwide injunctive relief. These lawsuits may eventually be consolidated if the case continues to move forward, as all 3 cases are relatively similar.
A complicated legal process will ensue as plaintiffs await their case's hearing during the February 21, 2025, preliminary hearing. Oregon Attorney General Dan Rayfield applauded the swift action taken by federal judge Angel Kelley to restrain the NIH’s new funding policy in a media release from the Oregon Department of Justice on Monday, February 10, 2025. “This legal victory underscores the importance of holding federal agencies accountable when their actions threaten the well-being of our communities,” said Rayfield.
So now we sit and wait, hoping beyond all hope that this nation continues to be a leader in medical and scientific research, that the thousands of dedicated researchers in this country can continue to provide innovative solutions to health conditions, and that our universities continue to have the opportunity to offer higher education for the thousands of brilliant students seeking to contribute their ideas.
I am grateful to Judge Angel Kelley for quickly imposing this temporary restraining order on the NIH funding policy changes. I am grateful for the states, universities, and organizations that have opposed these devastating cost reductions. However, regardless of our gratitude as a research community for enacting these checks and balances, we remain on edge while the judicial system fights against a policy that would have a devastating impact on medical and scientific research.
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.